Stockscreener 앱 받기
8.08
0.12%
0.010
시간 외 거래:
8.06
-0.02
-0.25%
전일 마감가:
$8.07
열려 있는:
$8.06
하루 거래량:
338.44K
Relative Volume:
0.24
시가총액:
$385.31M
수익:
-
순이익/손실:
$-82.60M
주가수익비율:
-3.9223
EPS:
-2.06
순현금흐름:
$-48.61M
1주 성능:
+0.12%
1개월 성능:
+2.02%
6개월 성능:
+288.46%
1년 성능:
+117.20%
1일 변동 폭
$8.06
$8.08
1주일 범위
$8.06
$8.10
52주 변동 폭
$1.312
$8.10
Vigil Neuroscience Inc Stock (VIGL) Company Profile
명칭
Vigil Neuroscience Inc
전화
857-254-4445
주소
100 FORGE ROAD, WATERTOWN
VIGL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
8.08 | 376.64M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-04 | 개시 | William Blair | Outperform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2022-09-16 | 개시 | Wedbush | Outperform |
| 2022-08-29 | 개시 | H.C. Wainwright | Buy |
| 2022-02-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 개시 | Jefferies | Buy |
| 2022-02-01 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-02-01 | 개시 | Stifel | Buy |
모두보기
Vigil Neuroscience Inc 주식(VIGL)의 최신 뉴스
What analysts say about Vigil Neuroscience Inc. stockConsistent high-yield stocks - Autocar Professional
What drives Vigil Neuroscience Inc. stock priceExtraordinary market timing - Autocar Professional
Is Vigil Neuroscience Inc. a good long term investmentRapid growth trajectories - Autocar Professional
Vigil Neuroscience Inc. Stock Analysis and ForecastFree Investment Timing Strategies - jammulinksnews.com
Vigil Neuroscience merger with Sanofi clears U.S. antitrust waiting period By Investing.com - Investing.com Nigeria
Vigil Neuroscience Awaits HSR Expiration for Sanofi Merger - TipRanks
Vigil Neuroscience merger with Sanofi clears U.S. antitrust waiting period - Investing.com Australia
How Vigil Neuroscience Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
Why Vigil Neuroscience Inc. stock attracts strong analyst attention10x Potential Stocks - Newser
What makes Vigil Neuroscience Inc. stock price move sharplyFree VIP Investment Strategies - Newser
Brokerages Set Vigil Neuroscience, Inc. (NASDAQ:VIGL) PT at $10.80 - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, CHTR, VIGL on Behalf of Shareholders - MarketScreener
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc.VIGL - The Globe and Mail
TREM2 agonists reported in Vigil Neuroscience patents - BioWorld MedTech
Vigil Neuroscience (NASDAQ:VIGL) Stock Price Up 0.4% – Here’s What Happened - Defense World
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: TASK, VIGL, STRM, and CHTR - The Malaysian Reserve
Vigil Neuroscience Announces Special Meeting for Sanofi Merger Vote - TipRanks
VIGL to Be Acquired by Sanofi for $8 Cash + $2 CVR; Vote Aug 4 2025 | VIGL SEC FilingForm DEFM14A - Stock Titan
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High? - Nasdaq
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
Two Sigma Investments LP Acquires 41,836 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders - MarketScreener
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet - MSN
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact (VIGL) - Seeking Alpha
Vigil Neuroscience fails in mid-stage study for lead asset - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders - marketscreener.com
Vigil Neuroscience halts Phase 2 trial for ALSP treatment By Investing.com - Investing.com South Africa
Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease - insights.citeline.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasda - Morningstar
Hold Rating on Vigil Neuroscience Inc Amidst Acquisition and Trial Outcomes - TipRanks
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm - GuruFocus
Vigil Neuroscience (VIGL) Trial Results Impact Future Plans - GuruFocus
Vigil Neuroscience halts Phase 2 trial for ALSP treatment - Investing.com Australia
Vigil Neuroscience Inc (VIGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):